Loading…
Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing medicines for patients living with rare diseases in the United States. It offers Firdapse for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); Fycompa, a novel non-competitive selective antagonist at the postsynaptic ionotropic alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid glutamate receptor that is used to treat focal onset seizures, as well as tonic-clonic seizure; and AGAMREE, a corticosteroid for the treatment of duchenne muscular dystrophy. The company has license agreements with BioMarin Pharmaceutical Inc.; and a collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $589M | $296M | $214M | $209M | 22.5% | 19.8% | 30.8% |
| 2024 | $492M | $233M | $164M | $239M | 22.5% | 23.5% | 129.5% |
| 2023 | $398M | $120M | $71M | $62M | 18.4% | 85.9% | -14.0% |
| 2022 | $214M | $103M | $83M | $116M | 27.7% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 214.20 | 398.20 | 491.73 | 588.99 |
| Operating Revenue | - | 214.20 | 398.20 | 491.73 | 588.99 |
| Cost Of Revenue | - | 34.39 | 51.97 | 68.84 | 87.25 |
| Gross Profit | - | 179.81 | 346.24 | 422.89 | 501.74 |
| Operating Expense | - | 77.97 | 259.42 | 227.76 | 243.96 |
| Research And Development | - | 19.79 | 93.15 | 12.65 | 12.71 |
| Selling General And Administration | - | 57.08 | 133.71 | 177.74 | 193.75 |
| Total Expenses | - | 112.36 | 311.39 | 296.61 | 331.21 |
| Operating Income | - | 101.84 | 86.81 | 195.12 | 257.78 |
| Total Operating Income As Reported | - | 101.84 | 86.81 | 195.12 | 257.78 |
| EBITDA | - | 103.08 | 119.69 | 232.90 | 295.65 |
| Normalized EBITDA | - | 103.08 | 119.69 | 227.82 | 294.68 |
| EBIT | - | 101.84 | 86.81 | 195.12 | 257.78 |
| Net Interest Income | - | - | 4.68 | 16.06 | 24.76 |
| Other Non Operating Income Expenses | 0.28 | 2.88 | 7.70 | - | - |
| Other Income Expense | - | 2.88 | 7.70 | 5.08 | 0.97 |
| Net Non Operating Interest Income Expense | - | - | 4.68 | 16.06 | 24.76 |
| Pretax Income | - | 104.72 | 94.51 | 216.26 | 283.52 |
| Tax Provision | - | 21.64 | 23.10 | 52.37 | 69.19 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 1.23 | 0.24 |
| Net Income Continuous Operations | - | 83.08 | 71.41 | 163.89 | 214.33 |
| Net Income From Continuing And Discontinued Operation | - | 83.08 | 71.41 | 163.89 | 214.33 |
| Net Income From Continuing Operation Net Minority Interest | - | 83.08 | 71.41 | 163.89 | 214.33 |
| Net Income | - | 83.08 | 71.41 | 163.89 | 214.33 |
| Net Income Common Stockholders | - | 83.08 | 71.41 | 163.89 | 214.33 |
| Net Income Including Noncontrolling Interests | - | 83.08 | 71.41 | 163.89 | 214.33 |
| Normalized Income | - | 83.08 | 71.41 | 160.04 | 213.59 |
| Diluted NI Availto Com Stockholders | - | 83.08 | 71.41 | 163.89 | 214.33 |
| Basic Average Shares | - | 103.37 | 106.28 | 118.46 | 122.29 |
| Diluted Average Shares | - | 111.38 | 113.75 | 124.94 | 127.26 |
| Reconciled Depreciation | - | 1.24 | 32.88 | 37.77 | 37.87 |
| Reconciled Cost Of Revenue | - | 34.25 | 51.65 | 68.45 | 86.88 |
| Total Unusual Items | - | - | 3.02 | 5.08 | 0.97 |
| Total Unusual Items Excluding Goodwill | - | - | 3.02 | 5.08 | 0.97 |
| Gain On Sale Of Security | - | - | 3.02 | 5.08 | 0.97 |
| Depreciation Amortization Depletion Income Statement | - | 1.10 | 32.56 | 37.38 | 37.50 |
| Depreciation And Amortization In Income Statement | - | 1.10 | 32.56 | 37.38 | 37.50 |
| General And Administrative Expense | - | 28.71 | 47.02 | 66.40 | 71.51 |
| Other Gand A | - | 22.54 | 34.25 | 45.92 | 48.94 |
| Salaries And Wages | - | 6.18 | 12.77 | 20.47 | 22.57 |
| Total Other Finance Cost | - | - | -4.68 | -16.06 | -24.76 |
| Selling And Marketing Expense | - | 29.47 | 86.69 | 111.34 | 122.24 |
| Amortization | - | 1.10 | 32.56 | 37.38 | 37.50 |
| Amortization Of Intangibles Income Statement | - | 1.10 | 32.56 | 37.38 | 37.50 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Catalyst Pharmaceuticals, Inc.this co. | CPRX | $3.8B | 17.87↓ discount | 4.01 | 22.5% | 10.56 |
| Amneal Pharmaceuticals, Inc. | AMRX | $4.3B | 59.86 | -60.93 | -101.8% | 11.13 |
| RadNet, Inc. | RDNT | $4.2B | -222.64 | 3.81 | -1.7% | 16.71 |
| Veracyte, Inc. | VCYT | $4.0B | 60.06 | 3.04 | 5.1% | 40.86 |
| Waystar Holding Corp. | WAY |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $3.9B |
| 34.60 |
| 1.00 |
| 2.9% |
| 13.55 |
| Merit Medical Systems, Inc. | MMSI | $3.8B | 29.27 | 2.37 | 8.1% | 12.46 |
| ACADIA Pharmaceuticals Inc. | ACAD | $3.7B | 9.51 | 3.03 | 31.9% | 30.83 |
| Organon & Co. | OGN | $3.5B | 18.82 | 4.68 | 24.9% | 8.98 |
| ICU Medical, Inc. | ICUI | $3.4B | 4607.08 | 1.59 | 0.0% | 14.73 |
| Peer Median | - | 31.93 | 2.70 | 4.0% | 14.14 | |